Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.
Jan. 14, 2021: Interpersonal violence history and adverse HIV outcomes; the incidence and severity of breast cancer; the effect of menopause on integrase-associated weight gain; two-drug therapy for HIV treatment-experienced people.
“ARCA started because there was a heartbreaking need for new drugs to treat HIV,” says Melanie Thompson, M.D. “The landscape for HIV research has indeed changed, largely as a result of our successes.”
Jan. 7, 2021: HIV status and COVID-19 disease severity; associations between tobacco smoking, cancer incidence, viral load, and CD4 count; immune recovery on integrase inhibitors; using smart pill bottles to boost adherence.
“You could think of this as ‘who is in and who is out,’ but in reality [restructuring] is more like changing chairs,” said Carl Dieffenbach, Ph.D.
The latest update to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV occurred within the perinatal HIV prevention guidelines on Dec. 20.
U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.
Dec. 17, 2020: HIV-related mortality in the U.S.; trends in extensive multidrug resistance; 96-week fostemsavir data; statins for microbial cancer prevention.
Dec. 10, 2020: Where the Ending the HIV Epidemic plan falls short; housing instability and HIV care incentives; financial wellbeing vs. health care access; San Diego's complex webs of HIV transmission.
In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.